Barclays raised the firm’s price target on HealthStream (HSTM) to $34 from $32 and keeps an Overweight rating on the shares. The firm says positive earnings call commentary more than offset the light Q3 and fiscal 2024 revenues. It continues to view HealthStream as a “relative safe haven within provider-facing health tech.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSTM:
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- HealthStream Reports Strong Q3 2024 Financial Results
- HealthStream reports Q3 EPS 19c, consensus 12c
- HealthStream cuts FY24 revenue view to $292M-$296M from $290M-$292M
- HSTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?